EdgarLookup

Citius Pharmaceuticals, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Citius Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q1 2026 Dec 31, 2025 $3.94M Feb 13, 2026
Q3 2014 Jun 30, 2014 $0 Aug 14, 2014
Q2 2014 Mar 31, 2014 $0 May 15, 2014
Q1 2014 Dec 31, 2013 $0 Feb 19, 2014
Q2 2014 Sep 30, 2013 $0 May 15, 2014
Q3 2014 Jun 30, 2013 $0 Aug 14, 2014
Q2 2014 Mar 31, 2013 $0 May 15, 2014
Q1 2014 Dec 31, 2012 $0 Feb 19, 2014
Q3 2013 Jun 30, 2012 $0 Sep 18, 2013
Q2 2013 Mar 31, 2012 $0 May 13, 2013
Q1 2013 Dec 31, 2011 $0 Feb 8, 2013
Q3 2012 Jun 30, 2011 $0 Aug 17, 2012
Q2 2012 Mar 31, 2011 $0 May 11, 2012
Q1 2012 Dec 31, 2010 $0 Feb 14, 2012

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q2 2025 Mar 31, 2025 ($11.51M) May 14, 2025
Q2 2025 Dec 31, 2024 ($10.28M) May 14, 2025
Q3 2024 Jun 30, 2024 ($10.57M) Aug 12, 2024
Q2 2025 Mar 31, 2024 ($8.54M) May 14, 2025
Q2 2025 Dec 31, 2023 $9.23M May 14, 2025
Q1 2024 Dec 31, 2023 ($9.23M) Feb 14, 2024
Q3 2024 Jun 30, 2023 ($8.48M) Aug 12, 2024
Q2 2024 Mar 31, 2023 ($10.53M) May 14, 2024
Q1 2024 Dec 31, 2022 ($3.59M) Feb 14, 2024
Q3 2022 Jun 30, 2022 ($8.86M) Aug 11, 2022
Q2 2022 Mar 31, 2022 ($7.56M) May 12, 2022
Q1 2023 Dec 31, 2021 ($9.23M) Feb 10, 2023
Q3 2022 Jun 30, 2021 ($5.82M) Aug 11, 2022
Q2 2022 Mar 31, 2021 ($4.12M) May 12, 2022
Q1 2022 Dec 31, 2020 ($8.15M) Feb 10, 2022
Q3 2021 Jun 30, 2020 ($4.68M) Aug 12, 2021
Q2 2021 Mar 31, 2020 ($4.42M) May 13, 2021
Q1 2021 Dec 31, 2019 ($4.32M) Feb 11, 2021
Q3 2020 Jun 30, 2019 ($4.41M) Aug 14, 2020
Q2 2020 Mar 31, 2019 ($3.63M) May 14, 2020

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q1 2026 Dec 31, 2025 ($9.02M) Feb 13, 2026
Q3 2025 Jun 30, 2025 ($8.79M) Aug 12, 2025
Q2 2025 Mar 31, 2025 ($11.26M) May 14, 2025
Q1 2026 Dec 31, 2024 ($10.04M) Feb 13, 2026
Q3 2025 Jun 30, 2024 ($10.63M) Aug 12, 2025
Q2 2025 Mar 31, 2024 ($10.97M) May 14, 2025
Q1 2025 Dec 31, 2023 ($9.34M) Feb 14, 2025
Q3 2024 Jun 30, 2023 ($8.67M) Aug 12, 2024
Q2 2024 Mar 31, 2023 ($10.69M) May 14, 2024
Q1 2024 Dec 31, 2022 ($7.25M) Feb 14, 2024
Q3 2023 Jun 30, 2022 ($8.92M) Aug 14, 2023
Q2 2023 Mar 31, 2022 ($7.59M) May 12, 2023
Q1 2023 Dec 31, 2021 ($9.26M) Feb 10, 2023
Q3 2022 Jun 30, 2021 ($5.98M) Aug 11, 2022
Q2 2022 Mar 31, 2021 ($4.19M) May 12, 2022
Q1 2022 Dec 31, 2020 ($8.16M) Feb 10, 2022
Q3 2021 Jun 30, 2020 ($4.69M) Aug 12, 2021
Q2 2021 Mar 31, 2020 ($4.43M) May 13, 2021
Q1 2021 Dec 31, 2019 ($4.45M) Feb 11, 2021
Q3 2020 Jun 30, 2019 ($4.43M) Aug 14, 2020